Hospitals | May 18, 2026
Medanta delivers record FY26 performance as revenue surges & profit jumps with expansion
Medanta expanded its bed capacity by 20% during the year
Medanta expanded its bed capacity by 20% during the year
Funding to support clinical development, gene therapy pipeline expansion and GMP manufacturing capabilities
Dr. Reddy’s is the first company to receive Health Canada approval for generic Semaglutide Injection in Canada
The company reported a 108% rise in profit after tax, driven by strong growth in regulated markets, branded generics, and U.S. expansion initiatives
Backed by Semaglutide launches, the company reported 47% quarter-on-quarter revenue growth in Q4 FY26, with EBITDA expanding more than fivefold
The company witnesses strong growth across its India, Africa, and emerging markets businesses, while securing regulatory approval for the first AB-rated gVentolin in the U.S. market
Famotidine Injection USP is a generic version of Pepcid injection to be manufactured at its Nagpur facility for the U.S. market
The certification follows an inspection conducted by the Malta Medicines Authority between January 29, 2026, and February 3, 2026
The target reach is of more than 30 million young people and caregivers across 21 countries
The study has shown that perioperative treatment with Imfinzi (durvalumab), alone or in combination with other immunotherapy agents
Subscribe To Our Newsletter & Stay Updated
